NO20080866L - Faststoff saltformer av pyrrol-substituert 2-indolinon - Google Patents

Faststoff saltformer av pyrrol-substituert 2-indolinon

Info

Publication number
NO20080866L
NO20080866L NO20080866A NO20080866A NO20080866L NO 20080866 L NO20080866 L NO 20080866L NO 20080866 A NO20080866 A NO 20080866A NO 20080866 A NO20080866 A NO 20080866A NO 20080866 L NO20080866 L NO 20080866L
Authority
NO
Norway
Prior art keywords
pyrrole
substituted
salt forms
indolinone
solid salt
Prior art date
Application number
NO20080866A
Other languages
English (en)
Norwegian (no)
Inventor
Changquan Calvin Sun
Michael Hawley
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20080866L publication Critical patent/NO20080866L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20080866A 2005-09-19 2008-02-18 Faststoff saltformer av pyrrol-substituert 2-indolinon NO20080866L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71858605P 2005-09-19 2005-09-19
PCT/IB2006/002506 WO2007034272A1 (en) 2005-09-19 2006-09-08 Solid salt forms of a pyrrole substituted 2-indolinone

Publications (1)

Publication Number Publication Date
NO20080866L true NO20080866L (no) 2008-03-13

Family

ID=37626412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080866A NO20080866L (no) 2005-09-19 2008-02-18 Faststoff saltformer av pyrrol-substituert 2-indolinon

Country Status (25)

Country Link
US (3) US20080275101A1 (pt)
EP (2) EP2112148A1 (pt)
JP (2) JP4519114B2 (pt)
KR (1) KR101050906B1 (pt)
CN (2) CN103601720B (pt)
AR (1) AR056521A1 (pt)
AU (1) AU2006293644B2 (pt)
BR (1) BRPI0616374B8 (pt)
CA (1) CA2621569C (pt)
CY (1) CY1109326T1 (pt)
DE (1) DE602006008015D1 (pt)
DK (1) DK1928858T3 (pt)
ES (1) ES2328407T3 (pt)
HK (1) HK1125101A1 (pt)
IL (1) IL189590A0 (pt)
MX (1) MX2008002415A (pt)
NO (1) NO20080866L (pt)
NZ (1) NZ566033A (pt)
PL (1) PL1928858T3 (pt)
PT (1) PT1928858E (pt)
RU (1) RU2399619C2 (pt)
SI (1) SI1928858T1 (pt)
TW (1) TWI310766B (pt)
WO (1) WO2007034272A1 (pt)
ZA (1) ZA200801431B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566033A (en) 2005-09-19 2011-04-29 Pfizer Prod Inc Solid salt forms of a pyrrole substituted 2-indolinone
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
CN102858739A (zh) 2010-03-10 2013-01-02 斯索恩有限公司 酰胺化吡咯甲酸酯化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6574293B1 (en) 1998-10-28 2003-06-03 Ericsson Inc. Receivers and methods for reducing interference in radio communications
AU784266B2 (en) * 1999-12-22 2006-03-02 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine kinase
ES2290117T3 (es) * 2000-02-15 2008-02-16 Sugen, Inc. Inhibidores de proteina quinasa 2-indolina sustituida con pirrol.
WO2002081466A1 (en) * 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP3168218B1 (en) * 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
AU2003216282A1 (en) * 2002-02-15 2003-09-09 Pharmacia And Upjohn Company Llc Process for preparing indolinone derivatives
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
NZ566033A (en) 2005-09-19 2011-04-29 Pfizer Prod Inc Solid salt forms of a pyrrole substituted 2-indolinone

Also Published As

Publication number Publication date
KR20080037093A (ko) 2008-04-29
PT1928858E (pt) 2009-09-17
US20120142749A1 (en) 2012-06-07
AU2006293644A1 (en) 2007-03-29
ES2328407T3 (es) 2009-11-12
RU2008109959A (ru) 2009-10-27
BRPI0616374B8 (pt) 2021-05-25
AR056521A1 (es) 2007-10-10
SI1928858T1 (sl) 2009-10-31
JP2010090152A (ja) 2010-04-22
JP4519114B2 (ja) 2010-08-04
US9290479B2 (en) 2016-03-22
ZA200801431B (en) 2009-07-29
TWI310766B (en) 2009-06-11
PL1928858T3 (pl) 2009-12-31
BRPI0616374B1 (pt) 2020-05-12
CN101287724A (zh) 2008-10-15
EP1928858A1 (en) 2008-06-11
CN103601720B (zh) 2016-08-10
DK1928858T3 (da) 2009-10-26
EP2112148A1 (en) 2009-10-28
US20080275101A1 (en) 2008-11-06
DE602006008015D1 (de) 2009-09-03
HK1125101A1 (en) 2009-07-31
CY1109326T1 (el) 2014-07-02
EP1928858B1 (en) 2009-07-22
NZ566033A (en) 2011-04-29
AU2006293644B2 (en) 2012-05-31
JP2007084540A (ja) 2007-04-05
KR101050906B1 (ko) 2011-07-20
RU2399619C2 (ru) 2010-09-20
CA2621569A1 (en) 2007-03-29
CN101287724B (zh) 2013-11-06
BRPI0616374A2 (pt) 2011-06-21
CN103601720A (zh) 2014-02-26
TW200745093A (en) 2007-12-16
WO2007034272A1 (en) 2007-03-29
US20150158849A1 (en) 2015-06-11
IL189590A0 (en) 2008-08-07
US8987320B2 (en) 2015-03-24
CA2621569C (en) 2010-10-19
MX2008002415A (es) 2008-03-27

Similar Documents

Publication Publication Date Title
HK1117518A1 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
EA200400183A1 (ru) Кристаллы, содержащие соль n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида с яблочной кислотой, способы их получения и их композиции
ATE449761T1 (de) Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
SMP200800011B (it) Forme cristalline di 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilammino)-benzammide
TW200800950A (en) Salts of 4-methyl-N-[3-(4-Methyl-Imidazol-1-YL)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-YL-pyrimidin-2-ylamino)-benzamide
ATE451363T1 (de) 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
ATE504567T1 (de) 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl-substitutierte 1-h-pyrrolderivate als säuresekretionshemmer
EA201000093A1 (ru) Производные пиридазинона
DE602006020482D1 (de) 1,5-substituierte indol-2-yl amidderivative
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA201000558A1 (ru) Производные имидазола
EA200901601A1 (ru) Производные пиридазинона
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
EA200900812A1 (ru) Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
EA201001243A1 (ru) Кристаллические формы n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамида и способы их получения
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
ATE491692T1 (de) 1-(imidazolin-2-yl)amino-1,2-diphenylethan- verbindungen zur bekämpfung von tierpestkrankheiten
CY1110771T1 (el) Αλατα και πολυμορφα μιας πυρρολο-υποκατεστημενης ινδολινονικης ενωσης
NO20080866L (no) Faststoff saltformer av pyrrol-substituert 2-indolinon
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
ATE424203T1 (de) Verwendung von inhibitoren des na+/h+ austauschers, subtyp 5 (nhe5) zur gedächtnisverbesserung
EA200901179A1 (ru) Замещённые тетрагидрохинолины

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application